Aug. 5 at 1:55 AM
$NKGN NKGen Biotech (OTC:NKGN) received FDA Expanded Access Protocol (EAP) approval for troculeucel to treat multiple neurodegenerative diseases including early AD, Parkinson’s, ALS, and others. The company also expanded its Phase 1/2a Alzheimer’s trial to Canada and Florida, boosting patient recruitment. In July, NKGen secured
$2M in funding from a Japanese investor to support trials and EAP. While delisted from Nasdaq in March, relisting efforts are underway. Acquisition of NKMax Korea, expected in August 2025, gives NKGen global IP and manufacturing control. Phase 1 data showed 92% of patients had stable or improved cognition, with biomarker and BBB penetration confirmed. Phase 2a results are expected late 2025–early 2026. NKGen remains significantly undervalued on the OTC despite major scientific and clinical milestones. With global neurodegenerative treatment potential, troculeucel positions NKGen as a top NK cell pioneer with billion-dollar upside.
